3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Plasma cell
1
Conditions
Multiple Myeloma
84
Lymphoma, Non-Hodgkin
28
Hodgkin Disease
20
Neoplasms, Plasma Cell
18
Myelodysplastic Syndromes
16
Precursor Cell Lymphoblastic Leukemia-Lymphoma
14
Leukemia, Lymphocytic, Chronic, B-Cell
14
Leukemia, Myeloid, Acute
13
Lymphoma
11
Leukemia
10
Myeloproliferative Disorders
8
Lymphoma, Follicular
8
Lymphoma, B-Cell, Marginal Zone
8
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
8
Burkitt Lymphoma
8
Lymphoma, Mantle-Cell
7
Lymphoma, Large-Cell, Immunoblastic
7
Lymphoma, Large B-Cell, Diffuse
6
Blast Crisis
6
Primary Myelofibrosis
5
Leukemia, Myelomonocytic, Chronic
5
Leukemia, Myeloid, Chronic-Phase
5
Immunoglobulin Light-chain Amyloidosis
5
Congenital Abnormalities
5
Recurrence
4
Lymphoma, T-Cell, Cutaneous
4
Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative
4
Hematologic Neoplasms
4
Paraproteinemias
3
Leukemia, Myeloid, Accelerated Phase
3
Interventions
Lenalidomide
4
Dexamethasone
4
Bortezomib
3
pomalidomide
2
Cyclophosphamide
2
ricolinostat
1
Zoledronic Acid
1
Vitamin D
1
Transplantation, Autologous
1
Melphalan
1
Granulocyte Colony-Stimulating Factor
1
Filgrastim
1
Calcium Dobesilate
1
Calcium
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Disease Progression
×
Granulocyte Colony-Stimulating Factor
×
Plasma cell
×
Clear all
NCT02043847
2024-11-13
BMT-03
University of Illinois at Chicago
Phase 1
Completed
12 enrolled
12 charts